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L-myc gene belonging to the myc family is an on-
cogene� localized to chromosome �p�4 and tho�ght 
to be activated d�ring late t�morigenesis [�� �]. Since 
the cloning of L-myc gene in �9�5� enormo�s amo�nt 
of research has been cond�cted to help el�cidate the 
role of this gene in h�man malignancy [�]. A possible 
role of the myc oncogene in the neoplastic transforma-
tion of the h�man thyroid gland has been investigated. 
Some researchers s�ggest that myc-oncogene altera-
tions might be involved in malign transformation of the 
h�man thyroids [4� 5]. The non-coding variation in 
the second intron of the L-myc gene� generating an 
EcoRI polymorphism� is associated with increased risk 
of seve ral t�mor types� altho�gh controversial res�lts 
have been reported [6� �]. Some of the res�lts s�gges-
ted that L-myc gene polymorphism had some infl�ence 
on the s�sceptibility to cancer. However� no st�dy on 
the relevance of L-myc gene polymorphism to thyroid 
carcinogenesis has yet been reported. Identification 
of s�sceptibility factors that predispose individ�als to 
thyroid cancer co�ld possibly give f�rther insight into 
the etiology of this malignancy. In this st�dy� we have 
tried to establish a relationship bet ween differentiated 
thyroid cancers and L-myc gene polymorphism. With 
this aim� we analyzed the L-myc gene stat�s of diffe-
rentiated thyroid cancer patients� m�ltinod�lar goiter 
patients and healthy people for a comparison.
MATERIALS AND METHODS
Material. Blood samples from patients operated 
for nod�lar �m�ltinod�lar� e�thyroid goiter in Istanb�l 
Medical Fac�lty� Haseki Ed�cational Hospital and 
Cerrahpaşa Medical Fac�lty in ��������5 were col-
lected and �sed. The st�dy pop�lation consisted of 
4� patients with benign thyroid nod�les incl�ding only 
goiter patients and �� patients with malignant nod�les� 
incl�ding 69 cases of papillary carcinoma �PC� and 
�� cases of follic�lar carcinoma �FC�. The diagnosis of 
differentiated thyroid carcinoma �papillary and follic�-
lar carcinomas� and m�ltinod�lar goiter patients was 
made by the pathological analysis of thyroid specimens 
after s�rgery. All patients �nderwent total or s�btotal 
�for a few benign goiter patients� thyroidectomy. None 
of the patients had a history of accidental or medical 
radiation expos�re. Control gro�p incl�ded patients of 
the general s�rgery and orthopedic clinics of the same 
hospital� which were being treated for non-neoplastic 
diseases s�ch as ing�inal hernia or tra�ma. All data� 
incl�ding pathological diagnoses� age� gender and 
s�rgical findings were recorded. S�bjects reporting 
cigarette smoking still in the year prior to examination 
were determined. Demographic data of patients and 
controls were shown in Table �. Blood samples were 
collected from all patients preoperatively and L-myc 
gene polymorphism was performed after obtaining 
the res�lt of pathological analysis.
Table 1. Demographic data of our study groups
Study groups Males n (%)
Females n 
(%) Total
Mean 
age 
(years)
Smoking 
history (+) 
n (%)
Controls 31 (32.6) 64 (67.4) 95 41.2 30 (31.6)
Follicular carcinomas 3 (23.1) 10 (76.9) 13 42.2 2 (15.4)
Papillary carcinomas 19 (27.5) 50 (72.5) 69 34.8 2 (2.9)
Multinodular goiter 9 (19.1) 38 (80.9) 47 40.8 1 (2.1)
Note. n = number of cases.
Isolation of DNA. Blood specimens from all 
s�bjects were collected into t�bes containing EDTA. 
DNA was isolated from the blood le�kocytes in �� ml 
EDTA by the method of Miller et al. based on sodi�m 
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dodecyl s�lphate lysis� ammoni�m acetate extraction 
and ethanol precipitation [�].
Polymerase Chain Reaction (PCR) for L-myc 
Oncogene. Template DNA ��.5��.� µg� was �sed 
in a PCR �nder sterile conditions. ��� ng of primer 
was �sed for the reaction — the forward primer was 
5’-AGT-TCA-CTC-ACA-GGC-CAC-AT-�’ and the 
reverse primer was 5’-TGC-ATA-TCA-GGA-AGC-TTG-
AG-�’ in a vol�me of 5� µl containing � mM MgCl�� 
5� mM KCl ��� mM Tris HCl �pH �.4� �.5 mM of each 
dNTP �MBI Fermentas� and � �nit of Taq DNA Poly-
merase �MBI Fermentas�. Amplification was performed 
in a DNA thermal cycler �MBI Fermentas�for �� cycles 
with denat�ration steps at 94 °C for �� s� annealing 
at 5� °C for � min and extension at �4 °C for � min. 
The PCR prod�ct exhibited a �6� base pair fragment. 
Amplification fragment was digested with 5 �nits EcoRI 
�MBI Fermentas� at �� °C for � h [9]. The digested DNA 
fragments were separated by gel electrophoresis on 
a �% agarose gel in � x Tris Borate EDTA b�ffer and 
DNA vis�alized by ethidi�m bromide staining. The re-
sponsible L-myc RFLP alleles were identified in each 
sample .The three genotypes were the LL homozygote 
appearing as �6�-base pair �bp� fragment� the LS 
heterozygote with �6�� �4�� and ��5-bp fragments 
and the SS homozygote with �4� and ��5-base pair 
fragments �Fig�re�.
– 267 bp
– 142 bp
– 125 bp
50 bp
marker LL LS LL LS SS
Figure. Direct vis�alization of PCR prod�cts by ethidi�m bro-
mide staining. A �6�-base pair L-myc fragment was amplified� 
cleaved with Eco RI and electrophoresed on a �% agarose gel. 
Res�lts for five representative tyroid cancer patients are shown. 
Molec�lar weight markers are at the left and the �nc�t �6� base 
pair L-allele� and �4� and ��5 base pair S allele are designated 
at the right
Statistical Analysis. Statistical analyses were 
performed �sing the SPSS version �.5 incl�ding the 
Chi Sq�are �χ�� test and Yate’s correction for genotype 
and allele freq�encies composition. Odds ratios and 
95% confidence intervals were calc�lated for all three 
genotypes.
RESULTS
The n�mber of females was higher in o�r thyroid 
patients than in control gro�ps. However� we were not 
able to find any possible correlation between genotype 
and possible risk factors like age� gender and smo-
king habit. Histologic classification of thyroid t�mors 
was as follows: 5�.5% papillary t�mors �69 patients�� 
��.�% follic�lar t�mors ��� patients�� �6.4% m�lti-
nod�lar goiter �4� patients�. Table � s�mmarizes the 
data of the overall proportion of the L-myc genotypes 
in control pop�lation and in patients with benign and 
malignant thyroid diseases.
Table 2. Comparison between the different L-myc genotypes in the control 
population and in the benign and malignant thyroid disease patients
Genotypes Controls, n (%)
Multinodular 
goiter, n (%)
Papillar 
cancer, n (%)
Follicular 
cancer, n (%)
LL 37 (38.9%) 24 (51.1%) 28 (40.6%) 3 (23.1%)
LS 47 (49.5%) 15 (31.9%) 30 (43.5%) 10 (76.9%)
SS 11 (11.6%) 8 (17.01%) 11 (15.9%) 0 (0%)
Total of cases 95 47 69 13
LL 37 (38.9% ) 26 ( 55.3% ) 28 ( 40.6% ) 3 (23.1% )
LS + SS 58 (61.1%) 21 (44.7%) 41 (59.4%) 10 (76.9%)
Note. n = number of cases.
There was no statistically significant difference 
fo�nd between vario�s types of thyroid disorders in 
regard to L-myc gene polymorphism expect in allele 
freq�encies among patients with benign and malign 
nod�les. The L-myc S allele tended to be more fre-
q�ent among the follic�lar thyroid cancer patients 
�freq�ency �6.9%� than among controls �6�.�%� b�t 
witho�t reaching a significant level. In o�r follic�lar 
thyroid cancer patients� the freq�ency of L-myc S allele 
was higher than it was in m�ltinod�lar goiter patients 
and the difference is statistically significant �χ� = 4.��� 
p = �.�4�. Patients with S allele �SS or LS genotypes� 
showed a �.96-fold �95% CI �.5���6.��6� risk for fol-
lic�lar thyroid cancer when compared with controls� 
and �.��-fold �95% CI �.95����.��6; p = �.�4� when 
compared with m�ltinod�lar goiter patients. 
DISCUSSION
L-myc is one of the three major members of the 
myc proto-oncogene family. These genes encode 
proteins that play distinct b�t overlapping roles in a 
wide range of normal and aberrant cell�lar processes 
incl�ding cell proliferation� differentiation� apoptosis 
and t�morigenesis [��� ��]. L-myc has been m�ch less 
intensively st�died than the other two members of the 
myc gene family� c-myc or N-myc. No previo�s st�dies 
have reported genetic polymorphism of L-myc gene 
associated with thyroid carcinomas. It is known that 
m�tations of genes involved in the control of cell�lar 
growth and/or differentiation� s�ch as c-myc� affect 
the development of thyroid neoplasms [4� 5]. The 
freq�ency of females was significantly higher in the 
st�dy pop�lation� as well as in the gro�ps of papillary 
and follic�lar cancer� which is in agreement with the 
gender distrib�tion �s�ally observed in this type of 
cancers [��]. B�rman et al. showed that c-myc onco-
gene expression is comparable in normal thyrocytes 
and in thyroid nod�les or thyroid cancer samples [��]. 
Those findings s�pport a role for c-myc in both nor-
mal and neoplastic thyrocyte growth. On the other 
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hand� a st�dy by Bieche et al. reported that none of 
the neoplastic thyroid samples overexpressed myc 
oncogene [�4]. 
The L-myc EcoRI polymorphism is a non-coding 
variation in the second intron of the L-myc gene res�l-
ting in S and L alleles. Individ�als carrying the S allele 
tend to have poor prognosis and increased risk of 
seve ral t�mor types� altho�gh controversial res�lts 
have been reported [6]. Since the first st�dy of the 
L-myc RFLP in �apanese l�ng cancer patients reported 
in �9��� many researchers have st�died the L-myc 
RFLP types in different cases of l�ng cancer and other 
malignant t�mors. Some of these st�dies have shown 
a positive relationship between L-myc genotypes and 
s�sceptibility to some types of cancer [�5���]� b�t other 
st�dies fo�nd no relationship between L-myc genotypes 
and s�sceptibility to the same and other types of can-
cer [�� ��]. These res�lts s�ggest that f�rther st�dies 
are req�ired to clarify the relationship between L-myc 
genotypes and s�sceptibility to cancer [�9]. The present 
st�dy indicated that there was no significant difference 
in the distrib�tion of L-myc RFLP between patients with 
thyroid cancer and control gro�p. The only positive find-
ing observed was for follic�lar thyroid cancer patients 
classified into two genotype gro�ps “LS type pl�s SS 
genotype” and “LL genotype”� where the “LS pl�s SS 
genotype” gro�p� which showed a higher val�e of rela-
tive risk� was tho�ght to be a higher risk gro�p compared 
with the “LL genotype” gro�p. We showed that having 
S allele �SS or LS genotype� ca�sed a �.96-fold risk of 
follic�lar thyroid cancer when compared with controls� 
which was �.��-fold risk on comparison with m�ltinod�-
lar goiter patients.
Altho�gh clinical and epidemiological feat�res are 
helpf�l� there are still no accepted serological markers 
that can help identify patients at risk for malignancy 
among individ�als with thyroid nod�les [��� ��]. The 
association of L-myc gene polymorphism with cancer 
s�sceptibility has prod�ced conflicting res�lts. This 
may have been d�e to racial/ethnic differences and 
methodological variations in the st�dies� s�ch as 
control selection and case stratification [��]. In o�r 
female patients� papillary and follic�lar carcinomas 
were two to fo�r times more freq�ent than men� as 
s�pported by the previo�s literat�re [��]� partic�larly 
in reprod�ctive years. This has lead to the hypothesis 
that female hormones or X chromosomal genes might 
be involved in the etiology or pathogenesis of the 
disease [��]. This hypothesis is s�pported by data of 
molec�lar genetic analysis of thyroid cancers� which 
also s�ggest the existence of different molec�lar 
mechanisms leading to papillary and follic�lar thy-
roid cancers [�4� �5]. Papillary and follic�lar t�mors 
sho�ld be examined separately for the identification of 
p�tative risk genotypes for thyroid cancer. Conversely� 
when considered alone� polymorphic L-myc gene is 
not strongly associated with thyroid cancer� as has 
been observed for other types of cancer. We s�ggest 
that L-myc genotype profiling together with other 
s�sceptibility factors� may be �sef�l in the screening 
for thyroid nod�le malignancy. 
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ПОЛИМОРФИЗМ ГЕНА L-MYC И РИСК РАЗВИТИЯ РАКА 
ЩИТОВИДНОЙ ЖЕЛЕЗЫ
Для ряда опухолей человека показана корреляция между риском развития опухоли и определенным вариантом гена L-MYC. 
Данные о наличии такой связи при раке щитовидной железы к настоящему времени отсутствуют. Цель: проанализиро-
вать распределение полиморфных типов гена L-MYC в популяции больных с доброкачественными и злокачественными 
поражениями щитовидной железы, включая рак щитовидной железы, в Турции. Методы: для анализа полиморфизма 
гена L-MYC использован метод молекулярного генотипирования, в частности, метод определения полиморфизма длины 
рестрикционных фрагментов, основанный на полимеразной цепной реакции (PCR-RFLP). Определение проводили в 
лейкоцитах 138 больных, в том числе 48 больных с узловым зобом, 13 больных фолликулярным раком щитовидной же-
лезы и 69 больных папиллярным раком. Контрольную группу составляли 109 здоровых лиц. Результаты: статистически 
достоверных различий в распределении исследуемых генотипов у больных с патологией щитовидной железы и здоровых 
лиц не выявили. Показано, что относительный риск фолликулярного рака щитовидной железы у больных-носителей 
генотипа SS или LS составляет 1,96 по сравнению со здоровыми лицами (при 95% доверительном интервале от 0,573 
до 6,706) и 3,11 по сравнению с больными с узловым зобом (при 95% доверительном интервале от 0,952 до 10,216) (р = 
0,04). Выводы: по нашему предположению, определение профиля полиморфизма гена L-MYC с учетом других факторов, 
определяющих предрасположенность к развитию опухолей, может быть полезным при скрининге озлокачествления узел-
ковых образований щитовидной железы. 
Ключевые слова: аллель, рак, L-myc, полиморфизм, щитовидная железа.
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